References
- Marples B, Collis SJ. Low-Dose Hyper-Radiosensitivity: Past, Present, and Future. Int J Radiat Oncol 2008; 70:1310-8; https://doi.org/10.1016/j.ijrobp.2007.11.071
- Zhang P, Wang B, Chen X, Cvetkovic D, Chen L, Lang J, Ma CM. Local tumor control and normal tissue toxicity of pulsed low-dose rate radiotherapy for recurrent lung cancer: An in vivo animal study. Dose Response 2015; 13:1559325815588507; PMID:26675811; https://doi.org/10.1177/1559325815588507
- Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-[beta] signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3:1011-22; PMID:15573100; https://doi.org/10.1038/nrd1580
- Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A, Pföhler J, Gross W, Peschke P, Hoeltgen L, Katus HA, Gröne HJ, Nicolay NH, Saffrich R, Debus J, Sternlicht MD, Seeley TW, Lipson KE, Huber PE. Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis. J Natl Cancer Inst 2017; 109:djw339; https://doi.org/10.1093/jnci/djw339
- Meyer JE, Finnberg NK, Chen L, Cvetkovic D, Wang B, Zhou L, Dong Y, Hallman MA, Ma CC, El-Deiry WS. Tissue TGF-beta expression following conventional radiotherapy and pulsed low-dose-rate radiation. Cell Cycle 2017; 16(12):1193-1200; PMID:28486014; https://doi.org/10.1080/15384101.2017.1317418
- Schaue D, McBride WH. Links between innate immunity and normal tissue radiobiology. Radiat Res 2010; 173:406-17; PMID:20334512; https://doi.org/10.1667/RR1931.1
- Naghavi AO, Johnstone PAS, Kim S. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Curr Probl Cancer 2016; 40(1):38-67; PMID:26656977; https://doi.org/10.1016/j.currproblcancer.2015.10.002